You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤三九(000999.SZ):擬受讓參股公司潤生藥業部分股權並向其增資
格隆匯 01-05 20:24

格隆匯1月5日丨華潤三九(000999.SZ)公佈,潤生藥業有限公司(簡稱“潤生藥業”“標的公司”或“目標公司”)是一家專注於呼吸用藥產品研發、生產的企業,為進一步豐富公司呼吸系統用藥,經華潤三九醫藥股份有限公司(簡稱“華潤三九”、“公司”)董事會2020年第三次會議審議通過,公司以自有資金對潤生藥業增資人民幣2億元,認購潤生藥業3,145.3665萬元新增註冊資本。

為豐富公司呼吸系統用藥,提升公司在呼吸領域的專業形象、進一步助力後續新品開發,公司受讓潤生藥業現有股東重慶渤溢新天股權投資基金合夥企業(有限合夥)(簡稱“渤溢基金”)所持潤生藥業780萬元註冊資本、曹原所持潤生藥業2000萬元註冊資本、重慶聚心投資有限公司(簡稱“聚心投資”)所持潤生藥業1520萬元註冊資本,受讓價格合計為人民幣5891萬元;同時,華潤三九向潤生藥業增資人民幣10,238.0952萬元,認購潤生藥業1609.7634萬元新增註冊資本,獲得本次股權轉讓及增資完成後潤生藥業4.1899%股權;上述資金來源均為公司自有資金。

重慶長生勝合醫藥私募股權投資基金合夥企業(有限合夥)(以下簡稱“長生勝合”)作為本輪投資人以與華潤三九相同的價格及條件,通過受讓潤生藥業部分股權及增資的方式一同對潤生藥業進行增持,其中長生勝合受讓潤生藥業現有股東曹原所持潤生藥業395萬元註冊資本、聚心投資所持潤生藥業680萬元註冊資本,受讓價格合計為人民幣1473萬元;長生勝合向潤生藥業增資人民幣2559.5238萬元,認購潤生藥業402.4408萬元新增註冊資本,獲得本次股權轉讓及增資完成後潤生藥業1.0475%股權。渤溢基金、曹原、聚心投資、長生勝合與公司無關聯關係。受讓參股公司部分股權並向其增資

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account